| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119859 | MERLION PHARMS GMBH | Methods for treating otic infections |
Jul, 2030
(6 years from now) | |
| US9993483 | MERLION PHARMS GMBH | Compositions and methods for treating ophthalmic, octic, or nasal infections |
Jul, 2030
(6 years from now) | |
| US8536167 | MERLION PHARMS GMBH | Methods for treating ophthalmic, otic, or nasal infections |
Aug, 2031
(7 years from now) | |
| US9504691 | MERLION PHARMS GMBH | Finafloxacin suspension compositions |
Nov, 2033
(10 years from now) | |
Xtoro is owned by Merlion Pharms Gmbh.
Xtoro contains Finafloxacin.
Xtoro has a total of 4 drug patents out of which 0 drug patents have expired.
Xtoro was authorised for market use on 17 December, 2014.
Xtoro is available in suspension/drops;otic dosage forms.
Xtoro can be used as treatment of acute otitis externa.
The generics of Xtoro are possible to be released after 21 November, 2033.
Drugs and Companies using FINAFLOXACIN ingredient
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS;OTIC
XTORO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic